argenx Reports First Quarter 2026 Financial Results and Provides Business Update
argenx reported Q1 2026 revenue of $1.3 billion, up 63% year-over-year, driven by VYVGART sales, with diluted EPS of $5.52 compared to $2.58 in the prior year. The company highlighted an upcoming PDUFA date of May 10, 2026, for anti-AChR antibody negative gMG, a key label expansion for its lead therapy.
Key figures
- Eps
- 5.52
- Revenue
- 1298000000
- Guidance
- PDUFA date for anti-AChR antibody negative gMG is May 10, 2026; Topline results from ALKIVIA (myositis) expected Q3 2026; Topline results from ADVANCE-NEXT (primary ITP) expected H1 2027
- Revenue Yoy
- 63%
- Operating profit
- 394000000
- Product net sales
- 1298000000
- Cash and equivalents
- 4300000000
- Total financial assets
- 4900000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.